Aims: Diabetes treatment algorithms recommend intensive intervention in those with a shorter duration of disease. Screening provides opportunities for earlier multifactorial cardiovascular risk factor control. Using data from the ADDITION-Leicester study (NCT00318032), we estimated the effects of this approach on modelled risk of diabetes-related complications in screen-detected patients.
| INTRODUCTION
Multifactorial cardiovascular risk factor intervention combining behaviour change, lifestyle modification, and often poly-pharmacotherapy is highly effective in selected high-risk patients with type 2 diabetes and is now considered standard practice in many countries. [1] [2] [3] [4] Theoretically, screening for type 2 diabetes provides a window of opportunity to deliver treatment earlier, before the onset of potentially less reversible cardiovascular pathology but when absolute risk is lower. 5 There is good evidence that this approach is effective at improving outcomes, and screen-detected populations are known to have worse cardiovascular risk factor control than comparable populations with conventionally diagnosed diabetes, an observation possibly reflecting limited opportunities for prior intervention in screened cases. [6] [7] [8] The Anglo-Danish-Dutch study of Intensive Treatment In peOple with Newly diagnosed screen detected Diabetes in primary care
(ADDITION-Europe) demonstrated that screening for type 2 diabetes is feasible and subsequent modelling studies have suggested modest improvements in coronary heart disease risk maybe sustained up to 10 years after identification through screening. 7, 9 To date, however, screening has not been shown to improve mortality in the short-term and longer follow-up of screened cohorts such as ADDITION-Europe are required. 10 Furthermore, predicted longer term trajectory of ischaemic heart disease, stroke, and congestive cardiac failure risk and its response to risk factor intensification amongst those initially identified through screening has not been described. This is important in light of recent evidence about the effectiveness of intensive multifactorial therapy in established type 2 diabetes.
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The ADDITION-Leicester study (NCT00318032), which contributed to ADDITION-Europe, focused screening in a particularly high risk multi-ethnic population and randomised newly diagnosed cases of type 2 diabetes to either intensive multifactorial intervention or standard treatment. 12 It has been suggested that screening programmes targeting specific populations known to be at higher risk of metabolic disease may be particularly effective. 13 In this analysis, we report 5-year outcomes of ADDITION-Leicester and use them to estimate differences in modelled risk for all-cause death, cardiovascular diseases (ischaemic heart disease, stroke, and congestive heart failure), and blindness using United Kingdom Prospective Diabetes Study outcomes risk prediction models. Serum creatinine concentration was determined by the modified kinetic Jaffe method. Urine albumin creatinine ratio was measured on spot urine specimens (preferably first void sample) using the Olympus OSR6167 Microalbumin Analyser (sensitivity of 0.46 mg/L). Neuropathy was assessed using the Michigan Neuropathy Screening Instrument which is a validated measure of distal symmetrical sensorimotor polyneuropathy. In addition to Michigan Neuropathy Screening Instrument, a clinical diagnosis of neuropathy was assumed when a prescription for lower limb neuropathic pain was issued during the trial (amitriptyline, gabapentin, pregabalin, duloxetine accepted). by an independent expert committee blinded to treatment allocation.
| Statistical analysis
We firstly summarised baseline and 5-year continuous variables as For the binary variables, differences were estimated with logistic regressions adjusted, when available, for baseline distributions.
Using previously published United Kingdom Prospective Diabetes
Study (UKPDS) risk equations (Supplementary Table S1 ), we estimated the absolute predicted risk for five outcomes: all-cause death, ischaemic heart disease, congestive heart failure, stroke, and blindness. We first calculated arm-specific predicted risk of event using baseline and 5-year data for a period of observation up to 20 years. Subsequently, for each year, we quantified between-arm difference (ie, treatment effect comparing intensive vs standard) with analysis of covariance.
All analyses were performed with Stata 15, and results are reported with 95% confidence interval (CI). We considered P < 0.05 statistically significant.
| RESULTS
Of 20 practices included in the study, nine were randomised to intensive management and 11 to standard care; after 5 years, information was available for 144 out of 146 (99%) and 192 out of 199 (97%) participants, respectively ( Figure 1 ). Five-year risk factors are summarised in Table S2 and Figure S1 ).
Arm-specific risk for each outcome up to 20 years of follow-up is depicted in Figure 2 . For both arms, the predicted risk comparing 5-year vs baseline was higher at any time points for the outcomes all-cause death, congestive heart failure, and blindness. Conversely, for stroke the risk was lower in intensive and higher in standard care; while for ischaemic heart disease both intensive and standard arms showed a reduced risk (Figure 2 ). Such findings translated in significant between-arm mean differences for ischaemic heart disease, congestive heart failure, and stroke and no treatment effect for all-cause death and blindness ( Figure 3 ). In particular, the modelled benefit of intensive versus standard care was progressively higher over-time for ischaemic heart disease (3.5% and 6.2% reduction at 10 and 20 years, respectively) and stroke (6.3% and 8.8% reduction), while the risk reduction for congestive heart failure plateaued at around 15 years (5.3% reduction). Here, we show in a screen-detected population that macrovascular and microvascular outcomes together with predicted FIGURE 2 Arm-specific differences in estimated risks UKPDS derived estimates of ischaemic heart disease, stroke, and importantly congestive cardiac failure risk are reduced in cases of type 2 diabetes identified via screening and then managed intensively for 5 years. Reduced risk in this group compared favourably with a less intensively managed control population, an effect that extended potentially to 20 years after diagnosis in our predictive modelling and would support the use of combined approaches to intervention in "early" type 2 diabetes.
As a result of insulin resistance and slow beta-cell decline, symptom-free hyperglycaemia and other obesity-related comorbidities often precede diagnosis of type 2 diabetes by many years, exposing the vasculature to unchecked and potentially irreversible damage. This so-called "metabolic memory" hypothesis has been advanced to explain why successive major trials have failed to convincingly demonstrate that glucose-lowering in isolation has a significant impact on mortality in people with established or advanced type 2 diabetes. 24 Screening theoretically shortens this untreated and presumed deleterious phase of type 2 diabetes by offering opportunities for earlier detection and intervention. The ADDITION-Europe study did not demonstrate any advantage of intensive management in this regard 5 years after identification of type 2 diabetes through screening. 10 As it could only compare treated newly identified cohorts (intensive and standard), it is argued that this study is unable to establish whether screening is truly beneficial in terms of reducing the risks of future cardiovascular morbidity and mortality. Subsequent complex simulation modelling of the ADDITION-Europe dataset suggests that earlier identification and intervention are likely to be beneficial in terms of cardiovascular morbidity and mortality. 6, 7 In the absence of long-term observational outcomes, we are reliant upon validated extrapolation models designed to assess the burden of disease over factors a year after diagnosis were the largest in this group, and unlike other intervention protocols, ADDITION-Leicester featured a diabetes specialist peripatetic clinic, supported glucose monitoring and a now nationally adopted structured education programme. 16, 25 The majority of multivariable risk prediction models are developed for the general population and are not specific to type 2 diabetes.
Clinical guidelines continue to recommend using UKPDS risk equations for cardiovascular disease prediction despite recent claims that they overestimate contemporary CHD risk. 26 We believe that the main message of sustained differences between standard and intensive multifactorial management approaches in screen-detected cases remains valid, even if the impact of the factors determining baseline risk may have changed since the UKPDS study.
One strength of the ADDITION-Leicester study is the large multiethnic population (41% South Asians) diagnosed with WHO defined type 2 diabetes following a population-level screening programme.
Other strengths of the study include the practice level randomisation process which limited contamination, the intensive nature of the intervention compared with other ADDITION-Europe centres, and participant retention of over 99% at 5 years. Our standard operating procedures enabled us to collect information for variables included in all the most recent UKPDS equations, including atrial fibrillation.
We searched primary and secondary care resources to obtain events and reduce missing data.
It is plausible that a number of limitations may have influenced the results obtained. Firstly, the data used in this analysis is derived from one centre with a specific ethnic makeup and method of diagnosis, so may not be directly applicable to other populations or settings. Secondly, inevitably there was some missing data for variables included in the UKPDS models, but attrition was relatively limited.
Thirdly, whilst this analysis demonstrates the potential benefits of aggressive cardiovascular risk factor modification in screen-detected patients, before judging overall impact, it is important to consider plausible adverse effects not accounted for by the simulation model.
For example, aggressive cardiovascular risk management may be associated with higher rates of iatrogenic hypoglycaemia and hypotension, both of which have been linked to worse outcomes and patient distress. Whilst in this study, intensive treatment at 1 year was not associated with an increase in self-reported hypoglycaemia or hospital admission for hypotension, careful consideration of these important adverse consequences would be required in clinical practice. It should also be appreciated that risk factor modification will inevitably inform equations modelled on this risk and does not reflect true outcomes or treatment effects. Future research should explore whether this modification of cardiovascular risk progression leads to a long-term reduction in actual events in this population.
| CONCLUSION
We have shown that intensive multifactorial intervention in screendetected cases of type 2 diabetes results in sustained improvements in modelled ischaemic heart disease and stroke outcomes. This effect is seen in a multi-ethnic population typical of those being invited for screening in the United Kingdom.
